Protagonist Therapeutics Stock Performance
| PTGX Stock | USD 79.73 2.07 2.53% |
Protagonist Therapeutics has a performance score of 3 on a scale of 0 to 100. The company holds a Beta of 0.59, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Protagonist Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Protagonist Therapeutics is expected to be smaller as well. Protagonist Therapeutics right now holds a risk of 2.06%. Please check Protagonist Therapeutics potential upside, as well as the relationship between the accumulation distribution and price action indicator , to decide if Protagonist Therapeutics will be following its historical price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Protagonist Therapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong technical and fundamental indicators, Protagonist Therapeutics is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 2.6 | Five Day Return (0.88) | Year To Date Return (6.17) | Ten Year Return 599.15 | All Time Return 599.15 |
1 | Is Protagonist Therapeutics Fairly Priced After Clinical Trial Updates and Big Share Price Surge | 11/11/2025 |
2 | Disposition of 10000 shares by Molina Arturo Md of Protagonist Therapeutics at 57.03 subject to Rule 16b-3 | 11/20/2025 |
3 | Is Protagonist Therapeutics Overvalued After Its Recent Biotech Rally A Fresh Look at the Valuation | 12/05/2025 |
4 | Acquisition by Dinesh Patel of 120200 shares of Protagonist Therapeutics at 87.18 subject to Rule 16b-3 | 01/06/2026 |
5 | Is It Too Late To Consider Protagonist Therapeutics After Its 119 percent One-Year Surge | 01/08/2026 |
6 | Disposition of 14299 shares by Selick Harold E of Protagonist Therapeutics at 4.21 subject to Rule 16b-3 | 01/13/2026 |
7 | State of Alaska Department of Revenue Sells 7,481 Shares of Protagonist Therapeutics, Inc. PTGX | 01/15/2026 |
8 | Disposition of 8588 shares by Asif Ali of Protagonist Therapeutics at 82.48 subject to Rule 16b-3 | 01/20/2026 |
9 | Protagonist Therapeutics CFO Asif Ali Sells 8,588 Shares | 01/22/2026 |
10 | A Look At Protagonist Therapeutics Valuation After Recent Insider Stock Sales By Top Executives | 01/26/2026 |
| Begin Period Cash Flow | 187 M | |
| Total Cashflows From Investing Activities | -299.5 M |
Protagonist | Build AI portfolio with Protagonist Stock |
Protagonist Therapeutics Relative Risk vs. Return Landscape
If you would invest 7,595 in Protagonist Therapeutics on November 3, 2025 and sell it today you would earn a total of 378.00 from holding Protagonist Therapeutics or generate 4.98% return on investment over 90 days. Protagonist Therapeutics is currently generating 0.0992% in daily expected returns and assumes 2.0555% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Protagonist, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Protagonist Therapeutics Target Price Odds to finish over Current Price
The tendency of Protagonist Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 79.73 | 90 days | 79.73 | about 85.1 |
Based on a normal probability distribution, the odds of Protagonist Therapeutics to move above the current price in 90 days from now is about 85.1 (This Protagonist Therapeutics probability density function shows the probability of Protagonist Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Protagonist Therapeutics has a beta of 0.59 indicating as returns on the market go up, Protagonist Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Protagonist Therapeutics will be expected to be much smaller as well. Additionally Protagonist Therapeutics has an alpha of 0.0866, implying that it can generate a 0.0866 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Protagonist Therapeutics Price Density |
| Price |
Predictive Modules for Protagonist Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Protagonist Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Protagonist Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Protagonist Therapeutics is not an exception. The market had few large corrections towards the Protagonist Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Protagonist Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Protagonist Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.09 | |
β | Beta against Dow Jones | 0.59 | |
σ | Overall volatility | 4.65 | |
Ir | Information ratio | 0.03 |
Protagonist Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Protagonist Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Protagonist Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Protagonist Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Protagonist Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: A Look At Protagonist Therapeutics Valuation After Recent Insider Stock Sales By Top Executives |
Protagonist Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Protagonist Stock often depends not only on the future outlook of the current and potential Protagonist Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Protagonist Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 65.1 M | |
| Cash And Short Term Investments | 418.9 M |
Protagonist Therapeutics Fundamentals Growth
Protagonist Stock prices reflect investors' perceptions of the future prospects and financial health of Protagonist Therapeutics, and Protagonist Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protagonist Stock performance.
| Return On Equity | 0.078 | ||||
| Return On Asset | 0.0182 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | (9.85) % | ||||
| Current Valuation | 4.42 B | ||||
| Shares Outstanding | 62.52 M | ||||
| Price To Earning | (4.81) X | ||||
| Price To Book | 7.72 X | ||||
| Price To Sales | 23.59 X | ||||
| Revenue | 434.43 M | ||||
| Gross Profit | 209.22 M | ||||
| EBITDA | 253.67 M | ||||
| Net Income | 275.19 M | ||||
| Cash And Equivalents | 291.89 M | ||||
| Cash Per Share | 5.95 X | ||||
| Total Debt | 10.87 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 7.59 X | ||||
| Book Value Per Share | 10.34 X | ||||
| Cash Flow From Operations | 184.15 M | ||||
| Earnings Per Share | 0.66 X | ||||
| Market Capitalization | 4.94 B | ||||
| Total Asset | 744.73 M | ||||
| Retained Earnings | (340.52 M) | ||||
| Working Capital | 544.24 M | ||||
| Current Asset | 83.24 M | ||||
| Current Liabilities | 6.43 M | ||||
About Protagonist Therapeutics Performance
Evaluating Protagonist Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protagonist Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protagonist Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -7.9 K | -8.3 K | |
| Return On Tangible Assets | 0.33 | 0.35 | |
| Return On Capital Employed | 0.33 | 0.34 | |
| Return On Assets | 0.33 | 0.35 | |
| Return On Equity | 0.37 | 0.39 |
Things to note about Protagonist Therapeutics performance evaluation
Checking the ongoing alerts about Protagonist Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protagonist Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protagonist Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Protagonist Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from simplywall.st: A Look At Protagonist Therapeutics Valuation After Recent Insider Stock Sales By Top Executives |
- Analyzing Protagonist Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protagonist Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protagonist Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protagonist Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protagonist Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protagonist Therapeutics' stock. These opinions can provide insight into Protagonist Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protagonist Stock Analysis
When running Protagonist Therapeutics' price analysis, check to measure Protagonist Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagonist Therapeutics is operating at the current time. Most of Protagonist Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagonist Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagonist Therapeutics' price. Additionally, you may evaluate how the addition of Protagonist Therapeutics to your portfolios can decrease your overall portfolio volatility.